ReviewBritish journal of pharmacology2011
New perspectives for the treatment of pulmonary hypertension.
Review in British journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 62 citations in OpenAlex.
- AMPK and the Challenge of Treating Hypoxic Pulmonary Hypertension.International journal of molecular sciences · 2022Review
- Current and emerging therapeutic approaches to pulmonary hypertension.Reviews in cardiovascular medicine · 2020Review
- Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial.JACC. Basic to translational science · 2020Article
- The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension.Frontiers in physiology · 2018Review
- Multiple mechanisms mediating carbon monoxide inhibition of the voltage-gated KCell death & disease · 2017Article
- BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.Cellular and molecular life sciences : CMLS · 2017Review
- Matrix metalloproteinases are possible targets in monocrotaline-induced pulmonary hypertension: investigation of anti-remodeling effects of alagebrium and everolimus.Anatolian journal of cardiology · 2017Article
- Strategies to increase nitric oxide signalling in cardiovascular disease.Nature reviews. Drug discovery · 2015Review
- Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS.British journal of pharmacology · 2015Review
- Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension.Circulation · 2014Article
- Animal Models of Pulmonary Hypertension: Matching Disease Mechanisms to Etiology of the Human Disease.Journal of pulmonary & respiratory medicine · 2014Article
- Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension.Pulmonary circulation · 2014Article
- Apelin inhibits the proliferation and migration of rat PASMCs via the activation of PI3K/Akt/mTOR signal and the inhibition of autophagy under hypoxia.Journal of cellular and molecular medicine · 2014Article
- A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?Pulmonary circulation · 2013Review
- Scleroderma lung disease.European respiratory review : an official journal of the European Respiratory Society · 2013Review
- Article
- BMPs and their clinical potentials.BMB reports · 2011Review
- Special issue of BJP on respiratory pharmacology.British journal of pharmacology · 2011Article
- Apoptosis signal-regulating kinase 1 inhibition inPulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Pulmonary hypertension (PH) is a debilitating disease with a poor prognosis. Therapeutic options remain limited despite the introduction of prostacyclin analogues, endothelin receptor antagonists and phosphodiesterase 5 inhibitors within the last 15 years; these interventions address predominantly the endothelial and vascular dysfunctionS associated with the condition, but simply delay progression of the disease rather than offer a cure. In an attempt to improve efficacy, emerging approaches have focused on targeting the pro-proliferative phenotype that underpins the pulmonary vascular remodelling in the lung and contributes to the impaired circulation and right heart failure. Many novel targets have been investigated and validated in animal models of PH, including modulation of guanylate cyclases, phosphodiesterases, tyrosine kinases, Rho kinase, bone morphogenetic proteins signalling, 5-HT, peroxisome proliferator activator receptors and ion channels. In addition, there is hope that combinations of such treatments, harnessing and optimizing vasodilator and anti-proliferative properties, will provide a further, possibly synergistic, increase in efficacy; therapies directed at the right heart may also offer an additional benefit. This overview highlights current therapeutic options, promising new therapies, and provides the rationale for a combination approach to treat the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.